Pipeline of Epigenetic Programs
Our pipeline is led by tazemetostat, an internally developed first-in-class EZH2 inhibitor, which is being evaluated in a robust clinical program that includes global clinical trials in patients with relapsed or refractory non-Hodgkin lymphoma (NHL), in adult and pediatric patients with certain genetically defined solid tumors and in patients with mesothelioma. Tazemetostat is also being evaluated in a front-line combination study with R-CHOP and an immuno-oncology combination study with Tecentriq™ (atezolizumab) in patients with diffuse large B-cell lymphoma, the most common form of NHL.
In addition, pinometostat, a clinical-stage DOT1L inhibitor, is being evaluated in a collaboration with Celgene for the treatment of pediatric MLL-r, a form of acute leukemia.
We are advancing discovery-stage wholly owned small molecule programs against novel HMT and other CMP targets. By 2020, we plan to have advanced at least three new oncology programs into clinical development, and expanded our preclinical pipeline.
Under collaboration agreements with Celgene and GlaxoSmithKline, we have developed an additional six small molecule oncology programs, including a potential first-in-class PRMT5 inhibitor with GlaxoSmithKline.
Our Internal Pipeline